Epidemiological studies in recent decades have revealed a significant increase in the number of patients with periodontal diseases leading to tooth loss. Modern realities require improvement of drug treatment of periodontitis. The antioxidant Selenase, selenium derivative, is an interesting treatment strategy for periodontitis. The study was carried out with the aim to evaluate the healing effectiveness of Selenase in rats with chronic generalized periodontitis (CGP) by its effect on markers of inflammation and cytoprotection. Experimental CGP was modulated in Wistar rats by a calcium-deficient diet with the inclusion of a prooxidant. Selenase (50 mcg/kg) and Mexidol (ethylmethylhydroxypyridine succinate, 250 mg/kg) were administered intragastrically for 30 days. Levels of IL-1β, HIF-1α, HSP70, and TNF-α were determined in the blood after treatment using the enzyme immunoassay method. Experimental CGP was characterized by the development of hyperemia, swelling, and bleeding of the gums; mobility of teeth; and gingival pockets up to 8 mm against the background of increased inflammatory markers (IL-1β, TNF-α), and molecular markers of cytoprotection (HIF-1α, HSP70) in the blood, indicating a homeostatic response of the periodontium in response to inflammation and subsequent hypoxia. Administration of Selenase to rats with CGP produced pronounced healing effects: the reduction in the depth of periodontal pockets by 42.55 %, cessation of bleeding, and disappearance of swelling against the background of a decrease of inflammatory markers: IL-1β – by 44.6 %, and TNF-α – by 65.9 % (p < 0.05). HIF-1α increased by 36.8 %, and HSP70 – by 71.1 % compared to those of the control group, which was not given the treatment (p < 0.05). The results obtained suggest a significant influence of Selenase on HSP70-dependent mechanisms of endogenous cytoprotection. The results of the study found that the use of Selenase in experimental CGP is more effective than Mexidol.
Read full abstract